Aeterna Zentaris announces 2.5 mln share 'at-the-market' issuance program
AcelRx pain treatment meets late-stage study goals
Oncolytics Biotech metastatic melanoma drug meets primary endpoint for first stage of U.S. Phase 2 trial
Aeterna Zentaris announces 2.5 mln share 'at-the-market' issuance program
AcelRx pain treatment meets late-stage study goals
Oncolytics Biotech metastatic melanoma drug meets primary endpoint for first stage of U.S. Phase 2 trial
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Circadian Technologies | 2 | 3 | 50 % |
| BioLife Solutions | 2 | 3 | 50 % |
| vascular imaging | 10 | 15 | 50 % |
| Ventana Medical Systems | 8 | 12 | 50 % |
| Genentech | 4 | 6 | 50 % |
| Coastal Pharmaceuticals | 3 | 5 | 67 % |
| Arrhythmia Research | 9 | 15 | 67 % |
| China Biologic | 3 | 5 | 67 % |
| Edge Therapeutics | 4 | 7 | 75 % |
| Purdue | 25 | 45 | 80 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Zytiga | 2 | 3 | 50 % |
| Medidata Solutions | 4 | 6 | 50 % |
| Vectura | 4 | 6 | 50 % |
| Spectrum Pharmaceuticals | 2 | 3 | 50 % |
| Bristol-Myers Squibb | 39 | 59 | 51 % |
| cafepharma | 27 | 41 | 52 % |
| Dentsply | 17 | 26 | 53 % |
| Sun Pharma | 30 | 47 | 57 % |
| Auxogyn | 7 | 11 | 57 % |
| Bioclinica | 7 | 11 | 57 % |